Judge: branded companies may be liable for generic versions

Share this article:
Philadelphia Common Pleas judge Mark Bernstein has ruled that branded drug companies may be liable for money spent on the generic version of their drugs when it is marketed for off-label uses. He ordered that claims against Warner-Lambert and Pfizer involving a generic version of Neurontin that was produced by a third-party manufacturer and marketed for off-label uses could continue to trial.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions